Form 4: Clover Health CFO's RSU Vesting Triggers Tax Share Withholding

Clover Health's Chief Financial Officer, Peter J. Kuipers, reported a disposition of 217,382 shares of Class A Common Stock due to tax withholding upon the vesting of restricted stock units.

Summary

• Clover Health's Chief Financial Officer, Peter J. Kuipers, reported a disposition of 217,382 shares of Class A Common Stock.
• The transaction occurred on July 29, 2025, at a price of $2.89 per share.
• This disposition was a non-discretionary event, with shares automatically withheld to cover tax obligations.
• The withholding was triggered by the vesting of 6.25% of time-based Restricted Stock Units (RSUs) that were originally granted to the CFO on April 29, 2024.
• Following this reported transaction, Peter J. Kuipers directly beneficially owns 6,132,591 shares of Class A Common Stock.
• The remaining RSUs are scheduled to vest in equal quarterly installments, commencing three months after July 29, 2025, and concluding on April 29, 2028, contingent on the CFO's continued service.

Sentiment

Score: 5

Explanation: This is a routine, non-discretionary transaction related to executive compensation. It does not indicate a positive or negative shift in company fundamentals or management's view of the company, but rather the execution of a pre-defined compensation plan.

Positives

• The transaction is a non-discretionary tax withholding, not a sale initiated by the CFO, indicating a routine compensation event.
• CFO Peter J. Kuipers retains a substantial direct beneficial ownership of 6,132,591 shares of Class A Common Stock after the transaction, demonstrating continued alignment with shareholder interests.
• The vesting of RSUs signifies the ongoing compensation and retention of a key executive within the company.

Negatives

• The CFO's direct beneficial ownership of Class A Common Stock decreased by 217,382 shares due to the tax withholding.

Future Outlook

Remaining Restricted Stock Units granted to the CFO are scheduled to vest in equal quarterly installments beginning three months after July 29, 2025, and concluding on April 29, 2028, subject to the CFO's continued service.

Industry Context

This transaction represents a standard executive compensation event, where shares are withheld to cover tax liabilities upon the vesting of restricted stock units. Such events are common across publicly traded companies in various industries as part of their long-term incentive plans for key personnel.

Stakeholder Impact

• Shareholders: The transaction represents a routine part of executive compensation, with shares withheld for tax purposes rather than a discretionary sale, which may be viewed neutrally.
• Employees: Reflects standard executive compensation practices, potentially reinforcing retention of key personnel.

Next Steps

• Remaining RSUs will continue to vest in equal quarterly installments until April 29, 2028, contingent on the CFO's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary tax withholding event related to the vesting of restricted stock units for the Chief Financial Officer. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction is a standard part of executive compensation and does not reflect a change in management's confidence or a significant shift in the company's outlook. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to buy or sell the stock.

Keywords

Clover Health, CLOV, Form 4, insider transaction, RSU, restricted stock units, tax withholding, executive compensation, Peter Kuipers